Cited by 402Breast Cancer Treatment StudiesEstrogen and related hormone effectsAdvanced Breast Cancer Therapies

The DOI matches its Crossref record.

Endocrine Treatment of Breast Cancer in Women

SANTEN, RICHARD J., MANNI, ANDREA, HARVEY, HAROLD, REDMOND, CAROL·1990·Endocrine Reviews

Open this paper in CoChat — free account

Abstract

Hormonal therapy for breast carcinoma began with the observation by George Beatson (1) in 1898 that bilateral oophorectomy caused tumor regression in selected premenopausal patients. Huggins and Bergenstal (2) later introduced surgical adrenalectomy as a form of hormone ablative treatment for postmenopausal women. To these methods were added surgical hypophysectomy and hormonal additive therapies such as the use of androgens, estrogens, progestins, and glucocorticoids (3). Since only one-third of patients experienced objective tumor regression with any of these hormonal therapies, clinicians began to favor use of cytotoxic chemotherapies in the 1960s and 1970s. During this time multiple chemotherapeutic regimens were developed which gained wide acceptance and enthusiastic support (3). However, when hormone receptor measurements were introduced in the mid-1970s, better selection of patients with hormonally responsive tumors became possible, and new impetus was provided for optimizing hormonal therapies. These developments led to the accumulation of a large body of clinical data regarding hormonal agents and provided clinicians with a broad armamentarium for the treatment of patients at the present time. We will summarize this information with the goals of highlighting specific endocrinological aspects of breast cancer treatment and providing practical perspective for choosing among various agents. Where recent comprehensive reviews are readily available, only pertinent concepts are highlighted.

Integrity signals

Registry

Crossref · 10.1210/edrv-11-2-221

Cites

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Sorted by citations

Items 101–200 of 402

Aromatase inhibition for ovarian stimulation: future avenues for infertility management
Mitwally, M. F., & Casper, R. F. (2002) · Current Opinion in Obstetrics & Gynecology · doi:10.1097/00001703-200206000-00003 · Cited by 71
Aromatase inhibitors ? mechanisms for non-steroidal inhibitors
BOSSCHE, H. V., Moereels, H., & Koymans, L. M. H. (1994) · Breast Cancer Research and Treatment · doi:10.1007/bf00682740 · Cited by 70
“At this dose ACTH-stimulated aldosterone levels were significantly blunted whereas basal aldosterone levels remained stable [ 40 ].”
Background
Open dose-finding study of a new potent and selective nonsteroidal aromatase inhibitor, CGS 20 267, in healthy male subjects
Trunet, P., Mueller, P., Bhatnagar, A. S., Dickes, I., Monnet, G., & White, G. E. (1993) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.77.2.8345034 · Cited by 69
Clinical Pharmacokinetics of Endocrine Agents Used in Advanced Breast Cancer
Lønning, P. E., Lien, E. A., Lundgren, S., & Kvinnsland, S. (1992) · Clinical Pharmacokinetics · doi:10.2165/00003088-199222050-00002 · Cited by 68
“These drugs suppress postmenopausal estrogen synthesis by inhibiting the final step, the conversion (aromatisation) of circulating androgens into estrogens (LImning et al. 1990; Santen et al. 1990).”
Background
Double-blind, randomised, multicentre endocrine trial comparing two letrozole doses, in postmenopausal breast cancer patients1Accepted as a poster presentation to the 34th Annual Meeting of the American Society of Clinical Oncology, May 1998, Los Angeles, U.S.A.1
Bajetta, E., Zilembo, N., Dowsett, M., Guillevin, L., Leo, A. D., Celio, L., Martinetti, A., Marchianò, A. V., Pozzi, P., Stani, S. C., et al. (1999) · European Journal of Cancer · doi:10.1016/s0959-8049(98)00392-x · Cited by 69
Direct effects of luteinizing hormone-releasing hormone agonists and antagonists on MCF-7 mammary cancer cells.
Segal-Abramson, T., Kitroser, H., Levy, J., et al. (1992) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.89.6.2336 · Cited by 69
p53 protein accumulation predicts poor response to tamoxifen therapy of patients with recurrent breast cancer.
Berns, E., Klijn, J. G. M., van Putten, W. L., de Witte, H. H., Look, M. P., Gelder, M. E. M., Willman, K., Portengen, H., Benraad, T. J., & Foekens, J. A. (1998) · Journal of Clinical Oncology · doi:10.1200/jco.1998.16.1.121 · Cited by 69
Breast Cancer Suppression by Progesterone Receptors Is Mediated by Their Modulation of Estrogen Receptors and RNA Polymerase III
Finlay-Schultz, J., Gillen, A. E., Brechbuhl, H. M., Ivie, J., Matthews, S. B., Jacobsen, B. M., Bentley, D. L., Kabos, P., & Sartorius, C. A. (2017) · Cancer Research · doi:10.1158/0008-5472.can-16-3541 · Cited by 66
Adaptation to Estradiol Deprivation Causes Up-Regulation of Growth Factor Pathways and Hypersensitivity to Estradiol in Breast Cancer Cells
Santen, R. J., Song, R. X.-D., Masamura, S., et al. (2008) · Advances in experimental medicine and biology · doi:10.1007/978-0-387-78818-0_2 · Cited by 67
Self-citation
Ovarian cysts in women receiving tamoxifen for breast cancer
Mourits, M. J. E., de Vries, E. G. E., Willemse, P. H. B., et al. (1999) · British Journal of Cancer · doi:10.1038/sj.bjc.6690280 · Cited by 67
Tamoxifen—What Next?
Gradishar, W. J. (2004) · The Oncologist · doi:10.1634/theoncologist.9-4-378 · Cited by 67
Aromatase and its inhibitors—an overview
Brodie, A. M. (1991) · The Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/0960-0760(91)90190-g · Cited by 65
Aromatase Inhibitors for the Treatment of Breast Cancer: A Journey from the Scratch
Ratre, P., Mishra, K., Dubey, A., Vyas, A., Jain, A. K., & Thareja, S. (2020) · Anti-Cancer Agents in Medicinal Chemistry · doi:10.2174/1871520620666200627204105 · Cited by 70
5-Aryl-1,2-dihydro-5H-chromeno[3,4-f]quinolines as Potent, Orally Active, Nonsteroidal Progesterone Receptor Agonists: The Effect of D-Ring Substituents
Edwards, J. P., West, S. J., Marschke, K. B., Mais, D. E., Gottardis, M. M., & Jones, T. K. (1998) · Journal of Medicinal Chemistry · doi:10.1021/jm9705770 · Cited by 64
Histone deacetylase inhibition and estrogen signalling in human breast cancer cells.
Margueron, R., Duong, V., Castet, A., & Cavaillès, V. (2004) · Biochemical Pharmacology · doi:10.1016/j.bcp.2004.04.031 · Cited by 96
Novel Methods and Tracers for Breast Cancer Imaging
Linden, H. M., & Dehdashti, F. (2013) · Seminars in Nuclear Medicine · doi:10.1053/j.semnuclmed.2013.02.003 · Cited by 64
Inhibition of growth of MDA-MB-231 human breast cancer xenografts in nude mice by bombesin/gastrin-releasing peptide (GRP) antagonists RC-3940-II and RC-3095
Miyazaki, M., Lamharzi, N., Schally, A. V., et al. (1998) · European Journal of Cancer · doi:10.1016/s0959-8049(97)10123-x · Cited by 63
Adenovirus-Mediated Delivery of a Dominant Negative Estrogen Receptor Gene Abrogates Estrogen-Stimulated Gene Expression and Breast Cancer Cell Proliferation
Lazennec, G., Alcorn, J. L., & Katzenellenbogen, B. S. (1999) · Molecular Endocrinology · doi:10.1210/mend.13.6.0318 · Cited by 63
“Since the growth of approximately 40% of all human breast cancers is dependent upon the presence of an estradiol-estrogen receptor (ER) complex (4, 5), there is currently intense interest in exploring different ways to functionally inactivate the ER.”
Background
Gonadotrophin-Releasing Hormone Agonists
Filicori, M. (1994) · Drugs · doi:10.2165/00003495-199448010-00005 · Cited by 60
Oestrogen receptor alpha increases p21(WAF1/CIP1) gene expression and the antiproliferative activity of histone deacetylase inhibitors in human breast cancer cells
Margueron, R., Licznar, A., Lazennec, G., Vignon, F., & Cavaillès, V. (2003) · Journal of Endocrinology · doi:10.1677/joe.0.1790041 · Cited by 60
“The implication of ovarian hormones in the development of breast cancer has been widely demonstrated and oestrogen dependency of these tumours has been successfully exploited to develop an antihormonal chemotherapy (Santen et al. 1990).”
Background
Use of aromatase inhibitors to increase final height
Dunkel, L. (2006) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2006.04.031 · Cited by 63
Estrogen Receptor-α Variant, ER-α36, is Involved in Tamoxifen Resistance and Estrogen Hypersensitivity
Zhang, X., & Wang, Z. (2013) · Endocrinology · doi:10.1210/en.2013-1116 · Cited by 57
Endocrine therapy in metastatic breast cancer
Kimmick, G. G., & Muss, H. B. (1998) · Cancer treatment and research · doi:10.1007/978-1-4615-6189-7_13 · Cited by 57
A discussion of the roles of oestrogen and progestin in human mammary carcinogenesis
King, R. J. B. (1991) · The Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/0960-0760(91)90030-9 · Cited by 57
Differential Regulation of Gene Expression by Estrogen in Estrogen Growth-Independent and -Dependent MCF-7 Human Breast Cancer Cell Sublines
Cho, H., Ng, P. A. B., & Katzenellenbogen, B. S. (1991) · Molecular Endocrinology · doi:10.1210/mend-5-9-1323 · Cited by 56
The Use of Aromatase Inhibitors for Ovulation Induction and Superovulation
Pavone, M. E., & Bulun, S. E. (2013) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2013-1328 · Cited by 57
Targeting luteinizing hormone-releasing hormone: A potential therapeutics to treat gynecological and other cancers
Ghanghoria, R., Kesharwani, P., Tekade, R. K., et al. (2016) · Journal of Controlled Release · doi:10.1016/j.jconrel.2016.11.002 · Cited by 55
The role of aromatase inhibitors in ameliorating deleterious effects of ovarian stimulation on outcome of infertility treatment
Mitwally, M. F., Casper, R. F., & Diamond, M. P. (2005) · Reproductive Biology and Endocrinology · doi:10.1186/1477-7827-3-54 · Cited by 55
Immunolocalization of liver receptor homologue-1 (LRH-1) in human breast carcinoma: Possible regulator of in situ steroidogenesis
Miki, Y., Clyne, C. D., Suzuki, T., Moriya, T., Shibuya, R., Nakamura, Y., Ishida, T., Yabuki, N., Kitada, K., Hayashi, S., et al. (2006) · Cancer Letters · doi:10.1016/j.canlet.2005.11.038 · Cited by 55
“It is well-known that progesterone inhibits cellular proliferation through PR [41], and administration of progestins is currently performed as an endocrine therapy in breast carcinoma patients [3], although some controversies exist with respect to progesterone actions in breast carcinoma [41,42].”
Background
Bombesin-like peptides and cancer
Preston, S. R., Miller, G. V., & Primrose, J. N. (1996) · Critical Reviews in Oncology/Hematology · doi:10.1016/1040-8428(96)00204-1 · Cited by 55
Hormonal Regulation of the Human Pepsinogen C Gene in Breast Cancer Cells
Balbı́n, M., & López-Otı́n, C. (1996) · Journal of Biological Chemistry · doi:10.1074/jbc.271.25.15175 · Cited by 54
“%) are initially responsive to anti-estrogen therapy (Santen et al., 1990).”
Background
Aromatase, Aromatase Inhibitors, and Breast Cancer
Brueggemeier, R. W. (2001) · American Journal of Therapeutics · doi:10.1097/00045391-200109000-00007 · Cited by 53
Cell biological factors associated with the response of breast cancer to systemic treatment
Klijn, J. G. M., Berns, E. M. J. J., Bontenbal, M., et al. (1993) · Cancer Treatment Reviews · doi:10.1016/0305-7372(93)90007-e · Cited by 54
Use of ultrasensitive recombinant cell bioassay to measure estrogen levels in women with breast cancer receiving the aromatase inhibitor, letrozole
Klein, K. O., Demers, L. M., Santner, S. J., Baron, J., Cutler, G. B., & Santen, R. J. (1995) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.80.9.7673408 · Cited by 54
Self-citation
Extracellular Signal-Regulated Protein Kinase, But Not c-Jun N-Terminal Kinase, Is Activated by Type II Gonadotropin-Releasing Hormone Involved in the Inhibition of Ovarian Cancer Cell Proliferation
Kim, K.-Y., Choi, K., Park, S., Auersperg, N., & Leung, P. C. K. (2005) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2004-1636 · Cited by 52
Influence of plasma estrogen levels on the length of the disease-free interval in postmenopausal women with breast cancer
Lønning, P. E., Helle, S. I., Johannessen, D. C., et al. (1996) · Breast Cancer Research and Treatment · doi:10.1007/bf01806162 · Cited by 53
“Estrogen suppression by castration in premenopausal women or use of aromatase inhibitors in postmenopausal women may cause tumor regression [3, 14].”
Background
Androgen receptor-mediated stimulation of 17 beta-hydroxysteroid dehydrogenase activity by dihydrotestosterone and medroxyprogesterone acetate in ZR-75-1 human breast cancer cells
Couture, P., Thériault, C., Simard, J., & Labrie, F. (1993) · Endocrinology · doi:10.1210/endo.132.1.8380373 · Cited by 54
To Block Estrogen's Synthesis or Action: That Is the Question
Santen, R. J. (2002) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.87.7.8589 · Cited by 54
“Direct clinical comparisons with the antiestrogen, tamoxifen, demonstrated equal efficacy for this indication (3).”
BackgroundSelf-citation
Glucocorticoids and androgens up-regulate the Zn-?2-glycoprotein messenger RNA in human breast cancer cells
López-Boado, Y. S., D�ez-Itza, I., Tolivia, J., & López-Otı́n, C. (1994) · Breast Cancer Research and Treatment · doi:10.1007/bf00666478 · Cited by 52
Liquid chromatography tandem mass spectrometry determination of free and conjugated estrogens in breast cancer patients before and after exemestane treatment
Zhao, Y., Boyd, J. M., Sawyer, M. B., & Li, X. (2013) · Analytica Chimica Acta · doi:10.1016/j.aca.2013.11.014 · Cited by 52
Bombesin family receptor and ligand gene expression in human colorectal cancer and normal mucosa
Chave, H., Gough, A. C., Palmer, K., et al. (2000) · British Journal of Cancer · doi:10.1054/bjoc.1998.0888 · Cited by 52
Benzo[a]pyrene-resistant MCF-7 human breast cancer cells. A unique aryl hydrocarbon-nonresponsive clone.
Moore, M., Wang, X., Lu, Y.-F., et al. (1994) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(17)32636-4 · Cited by 51
Aromatase inhibitors and breast cancer
Miller, W. R. (1997) · Cancer Treatment Reviews · doi:10.1016/s0305-7372(97)90037-2 · Cited by 51
Induction of estrogen independence of ZR-75-1 human breast cancer cells by epigenetic alterations.
van Agthoven, T., van Agthoven, T. L., Dekker, A., et al. (1994) · Molecular Endocrinology · doi:10.1210/mend.8.11.7533260 · Cited by 50
Cytotoxic analogs of luteinizing hormone-releasing hormone bind with high affinity to human breast cancers
Halmos, G., Nagy, A., Lamharzi, N., et al. (1999) · Cancer Letters · doi:10.1016/s0304-3835(98)00316-4 · Cited by 49
Effect of CGS 20267 on ovarian aromatase and gonadotropin levels in the rat
Sinha, S., Kaseta, J., Santner, S. J., Demers, L. M., Bremmer, W. J., & Santen, R. J. (1998) · Breast Cancer Research and Treatment · doi:10.1023/a:1005937900788 · Cited by 48
“Letrozole is a third generation aromatase inhibitor which is 3–4 orders of magnitude more potent than the first generation aromatase inhibitor, aminoglutethimide [4, 6].”
Background
Effect of nomegestrol acetate on estrone-sulfatase and 17β-hydroxysteroid dehydrogenase activities in human breast cancer cells
Chetrite, G. S., Pâris, J., Botella, J., et al. (1996) · The Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/0960-0760(96)00094-5 · Cited by 49
Specificity of Low Dose Fadrozole Hydrochloride (CGS 16949A) as an Aromatase Inhibitor
Santen, R. J., DEMERS, L. M., LYNCH, J., et al. (1991) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem-73-1-99 · Cited by 48
Self-citation
Mechanisms of Action and Cross-Talk Between Estrogen Receptor and Progesterone Receptor Pathways
Katzenellenbogen, B. S. (2000) · Journal of the Society for Gynecologic Investigation · doi:10.1177/1071557600007001s10 · Cited by 48
Administration of RU 486 for 8 days in normal volunteers: antiglucocorticoid effect with no evidence of peripheral cortisol deprivation.
Bertagna, X., Escourolle, H., Pinquier, J., Coste, J., Raux-Demay, M., Perles, P., Silvestre, L., Luton, J., & Strauch, G. (1994) · Journal of Clinical Endocrinology and Metabolism · doi:10.1210/jcem.78.2.8106625 · Cited by 50
Adaptive hypersensitivity to estrogen: mechanism for superiority of aromatase inhibitors over selective estrogen receptor modulators for breast cancer treatment and prevention.
Santen, R. J., Song, R., Zhang, Z., Kumar, R., Jeng, M. H., Masamura, S., Yue, W., & Berstein, L. M. (2003) · Endocrine Related Cancer · doi:10.1677/erc.0.0100111 · Cited by 48
“Wild-type MCF-7 and LTED cells were plated in six-well plates at a density of 60 × 10 cells/well in corresponding medium.”
InfluentialSelf-citation
Estrogen and progestin effects in human breast carcinogenesis
King, R. J. B. (1993) · Breast Cancer Research and Treatment · doi:10.1007/bf00683189 · Cited by 47
“Furthermore, some of the clinical effects of high dose progestins may be indirect via suppression of estrogen levels [8].”
BackgroundInfluential
Regulation of Oestrogen Action: Role of 17β-hydroxysteroid Dehydrogenases
POUTANEN, M. H., ISOMAA, V. V., Peltoketo, H., & Vihko, R. (1995) · Annals of Medicine · doi:10.3109/07853899509019255 · Cited by 46
Clinical breast cancer, new developments in selection and endocrine treatment of patients
Klijn, J. G. M., Berns, P. M. J. J., Bontenbal, M., et al. (1992) · The Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/0960-0760(92)90210-a · Cited by 46
Imaging Progesterone Receptor in Breast Tumors: Synthesis and Receptor Binding Affinity of Fluoroalkyl-Substituted Analogues of Tanaproget
Zhou, H., Lee, J., Mayne, C. G., et al. (2010) · Journal of Medicinal Chemistry · doi:10.1021/jm100052k · Cited by 45
Durable Remission of Leptomeningeal Metastasis of Breast Cancer with Letrozole: a Case Report and Implications of Biomarkers on Treatment Selection
Özdoğan, M. (2003) · Japanese Journal of Clinical Oncology · doi:10.1093/jjco/hyg046 · Cited by 45
“Letrozole is a non-steroidal aromatase inhibitor that effectively blocks aromatase enzyme without interfering with adrenal steroid biosynthesis (10,11).”
Background
Feasibility, endocrine and anti-tumour effects of a triple endocrine therapy with tamoxifen, a somatostatin analogue and an antiprolactin in post-menopausal metastatic breast cancer: a randomized study with long-term follow-up
Bontenbal, M., Foekens, J. A., Lamberts, S., et al. (1998) · British Journal of Cancer · doi:10.1038/bjc.1998.18 · Cited by 45
Mechanism for maintenance of high breast tumor estradiol concentrations in the absence of ovarian function: Role of very high affinity tissue uptake
Masamura, S., Santner, S. J., Gimotty, P. A., George, J., & Santen, R. J. (1997) · Breast Cancer Research and Treatment · doi:10.1023/a:1005714312092 · Cited by 45
Self-citation
Optimism versus pessimism predicts the quality of women's adjustment to early stage breast cancer
Carver, C. S., Pozo-Kaderman, C., Harris, S. D., Noriega, V., Scheier, M. F., Robinson, D. S., Ketcham, A. S., Moffat, F. L., & Clark, K. C. (1994) · Cancer · doi:10.1002/1097-0142(19940215)73:4 · Cited by 164
Overexpression of wild-type p53 gene renders MCF-7 breast cancer cells more sensitive to the antiproliferative effect of progesterone
Alkhalaf, M., & El‐Mowafy, A. M. (2003) · Journal of Endocrinology · doi:10.1677/joe.0.1790055 · Cited by 43
“The steroid hormone progesterone is an important growth regulator of normal and malignant breast epithelial cells, and is used to treat hormone-dependent breast tumors (Clarke & Sutherland 1990, Santen et al. 1990, Pasqualini et al. 1998, Sutherland et al. 1998).”
Background
Tobacco alkaloid derivatives as inhibitors of breast cancer aromatase
Kadohama, N., Shintani, K., & Osawa, Y. (1993) · Cancer Letters · doi:10.1016/0304-3835(93)90060-m · Cited by 42
Inhibition of the in vivo conversion of androstenedione to estrone by the aromatase inhibitor vorozole in healthy postmenopausal women.
van der Wall, E., Donker, T. H., Frankrijker, E. D., et al. (1993) · PubMed · Cited by 42
Repression of endogenous estrogen receptor activity in MCF-7 human breast cancer cells by dominant negative estrogen receptors.
Ince, B. A., Schodin, D. J., Shapiro, D. J., et al. (1995) · Endocrinology · doi:10.1210/endo.136.8.7628351 · Cited by 42
Adaptation of Estrogen-regulated Genes in Long-term Estradiol Deprived MCF-7 Breast Cancer Cells
Santen, R. J., Lobenhofer, E. K., Afshari, C. A., et al. (2005) · Breast Cancer Research and Treatment · doi:10.1007/s10549-005-5776-4 · Cited by 40
“Removal of the ovaries in pre-menopausal women lowers estradiol levels from an average of approximately 200 to 10 pg/ml and induces tumor regressions for an average of 12–18 months [9].”
BackgroundSelf-citation
Preparation, Resolution, and Biological Evaluation of 5-Aryl-1,2-dihydro-5H-chromeno[3,4-f]quinolines: Potent, Orally Active, Nonsteroidal Progesterone Receptor Agonists
Edwards, J. P., Zhi, L., Pooley, C. L. F., et al. (1998) · Journal of Medicinal Chemistry · doi:10.1021/jm980190c · Cited by 40
Synthesis and biological evaluation of some new A,B-ring modified steroidal d-lactones
Djurendić, E. A., Sakač, M. N., Savić, M. P., et al. (2008) · Steroids · doi:10.1016/j.steroids.2008.02.006 · Cited by 39
Type II Gonadotropin-Releasing Hormone Stimulates p38 Mitogen-Activated Protein Kinase and Apoptosis in Ovarian Cancer Cells
Kim, K.-Y., Choi, K., Park, S., Chou, C.-S., Auersperg, N., & Leung, P. C. K. (2004) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2003-031871 · Cited by 38
The role of progesterone metabolites in breast cancer: Potential for new diagnostics and therapeutics
Wiebe, J. P., Lewis, M. J., Cialacu, V., Pawlak, K. J., & Zhang, G. (2005) · The Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/j.jsbmb.2004.12.003 · Cited by 39
Effects of treatment with megestrol acetate, aminoglutethimide, or formestane on insulin-like growth factor (IGF) I and II, IGF-binding proteins (IGFBPs), and IGFBP-3 protease status in patients with advanced breast cancer
Frost, V. J., Helle, S. I., Lønning, P. E., van der Stappen, J. W. J., & Holly, J. M. P. (1996) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.81.6.8964854 · Cited by 39
Adaptive mechanisms induced by long-term estrogen deprivation in breast cancer cells
Song, R., Santen, R. J., Kumar, R., et al. (2002) · Molecular and Cellular Endocrinology · doi:10.1016/s0303-7207(02)00093-x · Cited by 38
Self-citation
Aryl Hydrocarbon (Ah) Nonresponsiveness in Estrogen Receptor-Negative MDA-MB-231 Cells Is Associated with Expression of a Variant Arnt Protein
Wilson, C., Thomsen, J. S., Hoivik, D. J., et al. (1997) · Archives of Biochemistry and Biophysics · doi:10.1006/abbi.1997.0289 · Cited by 38
Double-blind randomised trial comparing the non-steroidal aromatase inhibitors letrozole and fadrozole in postmenopausal women with advanced breast cancer
Tominaga, T., Adachi, I., Sasaki, Y., Tabei, T., Ikeda, T., Takatsuka, Y., Toi, M., Suwa, T., & Ohashi, Y. (2002) · Annals of Oncology · doi:10.1093/annonc/mdg014 · Cited by 38
The Rat Oncogenome: Comparative Genetics and Genomics of Rat Models of Mammary Carcinogenesis
Shull, J. D. (2007) · Breast Disease · doi:10.3233/bd-2007-28108 · Cited by 37
“The selective estrogen receptor (ER) modulator tamoxifen is widely used in the treatment of breast cancer [76], and has been demonstrated to reduce by approximately 50% the incidence of breast cancer in a population of women at high risk of the disease [22,23].”
Role of proliferation and apoptosis in net growth rates of human breast cancer cells (MCF‐7) treated with oestradiol and/or tamoxifen
Budtz, P. E. (1999) · Cell Proliferation · doi:10.1046/j.1365-2184.1999.3250289.x · Cited by 37
Antitumoral and endocrine effects of (+)-vorozole in rats bearing dimethylbenzanthracene-induced mammary tumors.
Coster, R. D., Ginckel, R. V., Callens, M., Goeminne, N., & Janssens, B. L. (1992) · PubMed · Cited by 36
What Is the Role of Ovarian Ablation in the Management of Primary and Metastatic Breast Cancer Today?
Prowell, T. M., & Davidson, N. E. (2004) · The Oncologist · doi:10.1634/theoncologist.9-5-507 · Cited by 36
“especially those with clinical features known to correlate with response to endocrine therapy, such as a long relapse-free interval and nonvisceral metastases [ 30 , 31].”
BackgroundResultInfluential
Plasma Membrane Receptors for the Cancer-Regulating Progesterone Metabolites, 5α-Pregnane-3,20-dione and 3α-Hydroxy-4-pregnen-20-one in MCF-7 Breast Cancer Cells
Weiler, P. J., & Wiebe, J. P. (2000) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.2000.2847 · Cited by 36
Additive endocrine therapy for advanced breast cancer – back to the future
Lønning, P. E. (2009) · Acta Oncologica · doi:10.3109/02841860903117816 · Cited by 35
“[38,39], the readers are referred to other reviews summarizing early development and clinical use of these compounds [40,41]; the subject of this review is to explore the potential for a new home for the orphans no longer belonging to the house of contemporary agents.”
Background
Importance of local aromatase activity in hormone-dependent breast cancer: a review
de Jong, P. C., Blankenstein, M. A., van de Ven, J., Nortier, J. W. R., Blijham, G. H., & Thijssen, J. H. H. (2001) · The Breast · doi:10.1054/brst.2000.0209 · Cited by 35
17β-Estradiol-mediated growth inhibition of MDA-MB-468 cells stably transfected with the estrogen receptor: Cell cycle effects
Wang, W., Smith, R., Burghardt, R. C., et al. (1997) · Molecular and Cellular Endocrinology · doi:10.1016/s0303-7207(97)00142-1 · Cited by 35
Breast cancer and expression of aromatase in breast adipose tissue
Bulun, S. E., & Simpson, E. R. (1994) · Trends in Endocrinology and Metabolism · doi:10.1016/1043-2760(94)90092-2 · Cited by 33
“Our results further underscore the importance of aromatase inhibitors as efficacious agents in the endocrine treatment of hormone-responsive breast cancer (Santen et al. 1990).”
Result
Rational use of agonists and antagonists of luteinizing hormone-releasing hormone (LH-RH) in the treatment of hormone-sensitive neoplasms and gynaecologic conditions
Schally, A. V., & Comaru‐Schally, A. M. (1997) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(97)00056-2 · Cited by 33
Cost Effectiveness of Letrozole in the Treatment of Advanced Breast Cancer in Postmenopausal Women in the UK
Nuijten, M. J. C., Meester, L., Waibel, F., & Wait, S. (1999) · PharmacoEconomics · doi:10.2165/00019053-199916040-00006 · Cited by 33
Effects of Tetramethoxystilbene on Hormone-Resistant Breast Cancer Cells: Biological and Biochemical Mechanisms of Action
Park, H.-Y., Aiyar, S. E., Fan, P., Wang, J., Yue, W., Okouneva, T., Cox, C., Jordan, M. A., Demers, L. M., Cho, H., et al. (2007) · Cancer Research · doi:10.1158/0008-5472.can-07-0056 · Cited by 33
“Two-thirds of breast cancers, when excised at the time of original diagnosis in women, contain estrogen or progesterone receptors (1).”
BackgroundInfluentialSelf-citation
A Novel Approach of Targeted Ablation of Mammary Carcinoma Cells Through Luteinizing Hormone Receptors using Hecate-CGβ Conjugate
Bodek, G., Rahman, N. A., Kaczmarek, M. M., et al. (2003) · Breast Cancer Research and Treatment · doi:10.1023/a:1023351819956 · Cited by 33
“Breast cancer is the most common malignancy in women, constituting 18% of all female cancers [1], and it is the leading cause of cancer-related death in women [ 2 ].”
Background
Aromatase inhibitors in breast cancer
Yue, W., Mor, G., Naftolin, F., et al. (2002) · CRC Press eBooks · doi:10.1201/b14733-8 · Cited by 33
Self-citation
Inhibition of growth of MCF-7 MIII human breast carcinoma in nude mice by treatment with agonists or antagonists of LH-RH
Yano, T., Korkut, E., Pinski, J., et al. (1992) · Breast Cancer Research and Treatment · doi:10.1007/bf01811962 · Cited by 33
“In recent years tamoxifen, a non-steroidal antiestrogen, has become the endocrine therapy of choice because of its efficacy and low toxicity, but it does not completely antagonize the effects of ovarian estrogens [3].”
BackgroundResultInfluential
Hypermethylation of the progesterone receptor A in constitutive antiprogestin-resistant mouse mammary carcinomas
Wargon, V., Fernandez, S. V., Goin, M., Giulianelli, S., Russo, J., & Lanari, C. (2010) · Breast Cancer Research and Treatment · doi:10.1007/s10549-010-0908-x · Cited by 33
“Two-thirds of breast cancers express estrogen receptor (ER) and progesterone receptor (PR) at the time of diagnosis [1].”
Background
Do endocrine treatments for breast cancer have a negative impact on lipid profiles and cardiovascular risk in postmenopausal women?
Lewis, S. J. (2007) · American Heart Journal · doi:10.1016/j.ahj.2006.10.034 · Cited by 32
Coexpression of Alternatively Spliced Estrogen and Progesterone Receptor Transcripts in Human Breast Cancer1
Balleine, R. L., Hunt, S. M. N., & Clarke, C. L. (1999) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.84.4.5637 · Cited by 31
Aromatase Inhibition and Breast Cancer
Miller, W. R. (2006) · Kluwer Academic Publishers eBooks · doi:10.1007/0-387-23761-5_14 · Cited by 31
Clinical use of aromatase inhibitors in human breast carcinoma
Santen, R. J. (1991) · The Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/0960-0760(91)90189-c · Cited by 31
Self-citation
Quantitative electrochemical detection of cathepsin B activity in breast cancer cell lysates using carbon nanofiber nanoelectrode arrays toward identification of cancer formation
Swisher, L. Z., Prior, A. M., Gunaratna, M. J., et al. (2015) · Nanomedicine Nanotechnology Biology and Medicine · doi:10.1016/j.nano.2015.04.014 · Cited by 30
Progesterone inhibits the migration and invasion of A549 lung cancer cells through membrane progesterone receptor α-mediated mechanisms
Xie, M., You, S., Chen, Q., et al. (2013) · Oncology Reports · doi:10.3892/or.2013.2336 · Cited by 29
“Administration of progestins, including medroxyprogesterone acetate, is currently used as an endocrine therapy in breast and endometrial carcinoma patients (8,9).”
Successful co‐treatment with LHRH‐agonist for ovarian over‐stimulation and cystic formation in premenopausal tamoxifen exposure
Cohen, I., Tepper, R., Figer, A., et al. (1999) · Breast Cancer Research and Treatment · doi:10.1023/a:1006184028515 · Cited by 29
Pharmacology of vorozole
Wouters, W., Ginckel, R. V., Krekels, M. D. W. G., et al. (1993) · The Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/0960-0760(93)90268-2 · Cited by 29
The future of antihormone therapy: innovations based on an established principle
Parczyk, K., & Schneider, M. R. (1996) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/bf01212877 · Cited by 29
“Tamoxifen is not only predominantly used as the first-line therapy in metastatic breast cancer, but for several years it has also been used in adjuvant treatment (Jordan 1993, for review; Santen et al. 1990).”
Influential
Influence of aminoglutethimide on plasma oestrogen levels in breast cancer patients on 4-hydroxyandrostenedione treatment
Lønning, P. E., Dowsett, M., Jones, A. L., Ekse, D., Jacobs, S., McNeil, F., Johannessen, D. C., & Powles, T. J. (1992) · Breast Cancer Research and Treatment · doi:10.1007/bf01831476 · Cited by 29
“Postmenopausal oestrogen synthesis occurs in peripheral tissue where circulating androgens are converted to oestrogens by the process called aromatisation [1].”
Background
Growth inhibition of MCF-7 human breast cancer cells by progesterone is associated with cell differentiation and phosphorylation of Akt protein
Alkhalaf, M., El‐Mowafy, A. M., & Karam, S. M. (2002) · European Journal of Cancer Prevention · doi:10.1097/00008469-200210000-00011 · Cited by 28
“Progestins are known to regulate the proliferation of hormone target tissues (e.g. uterus and breast) in both in vitro and in vivo systems (Clarke and Sutherland, 1990), and are used routinely as an endocrine therapy of human breast cancer (Santen et al., 1990).”
MORTYN JONES MEMORIAL LECTURE
Parker, M. G. (1993) · Journal of Neuroendocrinology · doi:10.1111/j.1365-2826.1993.tb00476.x · Cited by 28

Authors: SANTEN, R. J., MANNI, A., HARVEY, H., & REDMOND, C.
Affiliations: Pennsylvania State University (US)
Corresponding author: SANTEN, RICHARD J.
ORCID: SANTEN, RICHARD J.
Venue: Endocrine Reviews
Publisher: The Endocrine Society
Published: 1990-05
Volume: 11
Issue: 2
Pages: 221-265
ISSN: 0163-769X (ISSN-L)
1945-7189
DOI: 10.1210/edrv-11-2-221
OpenAlex: W2114712559
Cited by: 399
References: 0
Citations by year: 2026: 3 · 2025: 1 · 2024: 2 · 2023: 2 · 2022: 3 · 2021: 1 · 2020: 5 · 2018: 4 · 2017: 3 · 2016: 3 · 2015: 7 · 2014: 5 · 2013: 11 · 2012: 4
FWCI: 11.36
Type: journal article
Language: en
Open access: closed
Locations: Endocrine Reviews (publishedVersion)
PubMed (publishedVersion)
Topics: Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Breast Cancer Treatment Studies
Life Sciences › Biochemistry, Genetics and Molecular Biology › Endocrinology › Estrogen and related hormone effects
Health Sciences › Medicine › Oncology › Advanced Breast Cancer Therapies
Keywords: breast cancer, endocrine therapy, hormone therapy, oophorectomy, adrenalectomy, hypophysectomy, androgens, estrogen, progestins, glucocorticoids, tumor regression, treatment selection
MeSH terms: Androgens, Breast Neoplasms, Estrogen Antagonists, Estrogens, Female, Glucocorticoids, Humans, Progestins

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Endocrine Treatment of Breast Cancer in Women

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cited by

Related

Metadata

Record

About these checks